Velan Capital Sells $4.1 Million Worth of Mineralys Therapeutics Shares
According to an SEC filing dated May 15, 2026, Velan Capital Investment Management LP sold 140,000 shares in the first quarter of its position in clinical-stage biopharmaceutical company Mineralys Therapeutics (MLYS), valued at $4.1 million based on average quarterly pricing. The sale reduced Velan's stake to 11,000 shares worth approximately $297,990 as of quarter-end.
Tickers: $MLYS
Topics: investment portfolio changes stock trading